+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

Partial Paralysis And Muscle Weakness - Pipeline Insight, 2025 - Product Thumbnail Image

Partial Paralysis And Muscle Weakness - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Smith-Lemli-Opitz Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Smith-Lemli-Opitz Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
5-HT2B Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT2B Antagonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
5-HT6 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT6 Antagonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
5-HT7 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT7 Antagonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2025 - Product Thumbnail Image

Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Alpha-Synuclein (alphaSyn Or SNCA) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha-Synuclein (alphaSyn Or SNCA) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Retinoic Acid Receptors (RARs) Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Retinoic Acid Receptors (RARs) Agonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Lebers Hereditary Optic Neuropathy (lhon) - Pipeline Insight, 2025 - Product Thumbnail Image

Lebers Hereditary Optic Neuropathy (lhon) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Restless Leg Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Restless Leg Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Lou Gehrig's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Lou Gehrig's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
LRRK2 Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

LRRK2 Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
MELAS Sundrome - Pipeline Insight, 2025 - Product Thumbnail Image

MELAS Sundrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
GABA A Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

GABA A Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Dopamine D2 Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Dopamine D2 Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Traumatic Brain Injury - Epidemiology Forecast - 2034 - Product Thumbnail Image

Traumatic Brain Injury - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 60 Pages
  • Global
From
Alzheimer's Disease (AD) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Alzheimer's Disease (AD) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 157 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more